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for treatment of recurrent stenosis after eversion
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Belgrade, Serbia; and Zurich, Switzerland
Objective: This study was conducted to determine the efﬁciency and long-term durability of percutaneous transluminal
angioplasty and carotid artery stenting in carotid restenosis (CR) treatment after eversion endarterectomy, with emphasis
on variables that could inﬂuence the outcome.
Methods: We analyzed 319 patients (220 asymptomatic and 99 symptomatic) who underwent carotid angioplasty from
2002 until 2012 for CR that occurred after eversion endarterectomy. During this period, 7993 eversion endarterectomies
were done for signiﬁcant carotid artery stenosis. Signiﬁcant CR was detected by ultrasound examination and conﬁrmed by
digital subtraction angiography or multidetector computed tomography angiography. After angioplasty (with or without
stenting), color duplex ultrasound imaging was done after 1 month, 6 months, 1 year, and annually thereafter. End points
encompassed myocardial infarction, stroke, and cardiovascular death (fatal myocardial infarction, fatal cardiac failure,
fatal stroke), and also puncture site hematoma and recurrent restenosis. Primary end points were analyzed as early results
(#30 days after the procedure), and secondary end points were long-term results (>30 days). Variables and risk factors
inﬂuencing the early-term and long-term results were also analyzed. Median follow-up was 49.8 6 22.8 months (range,
17-121 months).
Results: All but one procedure ended with a technical success (99.7%). In the early postoperative period, transient ischemic
attack occurred in 2.8% of the patients and stroke in 1.6%, followed by one lethal outcome (0.3%). Stent thrombosis
occurred in one patient (0.3%) several hours after the angioplasty, followed by urgent surgery and graft interposition. In
the long-term follow-up, there were no transient ischemic attacks or strokes, non-neurologic mortality was 3.13%, and the
recurrent restenosis rate was 4.4%. The rate of non-neurologic outcomes during the follow-up was signiﬁcantly higher in
asymptomatic patients than in symptomatic patients (4.54% vs 0%; P [ .034). The statically highest rate of transient
ischemic attack was veriﬁed in patients in whom Precise (Cordis Corporation, New Brunswick, NJ) stents was used
(12.2%) and a Spider Fx (Covidien, Dublin, Ireland) cerebral protection device (12.5%) was used. Female gender, cor-
onary artery disease, plaque calciﬁcations, and smoking history were associated with an adverse outcome after angioplasty.
Conclusions: Carotid artery stenting is safe and reliable procedure for CR after eversion endarterectomy treatment, with
low rate of postprocedural complications. Type of stent and cerebral embolic protection device may inﬂuence the rate of
postprocedural neurologic ischemic events. (J Vasc Surg 2014;60:645-51.)Carotid endarterectomy (CEA) is an effective and reli-
able procedure for stroke prevention in symptomatic and
asymptomatic patients with severe carotid stenosis.1,2
However, one of the major complications that occurs and
thereby inﬂuences early and late neurologic ischemic events
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://dx.doi.org/10.1016/j.jvs.2014.03.288symptomatic restenosis after CEA ranges from 0.6% to
3.6%, and the reported incidence of asymptomatic resteno-
sis is 8.8% to 19%.3-5 Most authors agree that symptomatic
CR necessitates intervention, but the issue of asymptomatic
CR treatment remains controversial.6
The therapeutic options for CR are percutaneous trans-
luminal angioplasty (PTA), with or without carotid artery
stenting (CAS), and repeated open surgical treatment.
Some authors have reported satisfactory results of redo sur-
gery, but the surgery still has a higher rate of postoperative
complications compared with surgery for primary athero-
sclerotic lesions.7-10 PTA is considered to be a less invasive
procedure for CR treatment, with low rate of postproce-
dural stroke and mortality.11-14 In most of these studies,
however, the number of treated patients has been too
low and follow-up has been limited.
The aim of the present study was to determine the early
results and long-term durability of carotid PTA in CR
treatment after eversion CEA (eCEA), with an emphasis
on the predictive value of variables that could inﬂuence
the outcome.645
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The current study is a retrospective review of prospec-
tively collected data at the University Vascular Surgery
Clinic in Belgrade, Serbia. From 2002 until 2012, 319 pa-
tients received carotid PTA for signiﬁcant CR. During this
period, 7993 eCEAs were performed for signiﬁcant carotid
stenosis, for a signiﬁcant restenosis treated patient rate of
3.99% (319 patients). The Ethics Committee of the institu-
tion approved this study, and all patients provided written
informed consent.
CR occurred in all patients after eCEA. The technique
of eCEA is described in detail elsewhere.15 During the
follow-up after treatment, all patients underwent color
duplex examination using an Alfa10 color duplex system
(Aloka Co Ltd, Tokyo, Japan) at 1 month, after 6 months,
and then annually thereafter.
The ultrasound criteria to determine CR were (1) peak
systolic velocity >215 cm/s, corresponding to >50% reste-
nosis, and (2) peak systolic velocity >275 cm/s, corre-
sponding to >70% restenosis.16 Carotid artery restenosis
was considered signiﬁcant in symptomatic patients if a
diameter reduction of >50% was detected and was consid-
ered signiﬁcant in asymptomatic patients with a >85%
reduction. Apart from the hemodynamic characteristics,
color duplex ultrasound assessed the morphology of the
plaque, including quality of the plaque and surface irregu-
larity and ulceration. Patients with residual restenosis were
not included in the study.
The patients with CR after the initial CEA were consid-
ered symptomatic if they experienced transient ischemic
attack (TIA), stroke, or amaurosis fugax #6 months before
the ultrasound assessment and clinical admission.
In all patients for whom the ultrasound imaging
detected signiﬁcant CR, the lesions were additionally eval-
uated with digital subtraction angiography (Siemens,
Erlangen, Germany) from 2002 to 2005 and with multide-
tector computed tomography (CT) angiography (Light-
speed VCT; GE Healthcare, Milwaukee, Wisc) from
2005 to 2012.
CT was necessary to identify any aortic arch and supra-
aortic branch pathologies and for treatment planning. All
patients were examined by the institution’s attending
neurologist, and brain CT was performed before or upon
admission and after the angioplasty in patients with post-
procedural neurologic ischemic events.
Endovascular technique and procedural manage-
ment. The indication for treatment was made interdis-
ciplinarily with consensus among a vascular surgeon,
interventional radiologist, and neurologist. Acetylsalicylic
acid (100 mg/d) and clopidogrel (75 mg/d) or ticlopidine
(250 mg twice daily) were administered$3 days before the
intervention to prevent thrombosis and embolic complica-
tions. Patients who were immobile after the procedure
(stroke, puncture site hematoma, etc) were administered
low-molecular-weight heparin at a thrombosis prophylaxis
dose. After primary eCEA, 90.9% of the patients received
statins on discharge, 91.6% received acetylsalicylic acid(100 mg/d), and 27.6% received clopidogrel (75 mg/d)
when speciﬁed. All patients received statins and dual-
antiplatelet therapy after CAS.
The PTA and stenting were performed according to
our standardized operating procedure. All procedures
were performed under local anesthesia. The femoral artery
was the most commonly used access site, but if indicated,
the radial or brachial artery was used as well. After heparin
(100 IU/kg) administration, the access artery was punc-
tured, the sheath was introduced, and the guidewire was
passed through the aorta into the arch. A carotid angio-
gram was performed, and if the position was appropriate,
we continued with the procedure.
For the common carotid artery access, a 6F or 7F
sheath was placed, and the guidewire was passed through
the area of carotid narrowing. Embolic protection device
was then introduced to prevent debris and embolic compli-
cations. The type of embolic protection device used
depended on anatomical characteristics, plaque embolic
potentials, and localization and degree of the stenosis. If
very tight stenosis was to be treated, coronary balloons
were used for predilation; otherwise, direct stenting was
done with self-expanding stents, followed by balloon an-
gioplasty of the appropriate size. The balloon sized ranged
from 5  15 mm to 8  30 mm, with the most commonly
used size being 6  20 mm. After the procedure, the pro-
tection device, guidewires, and the sheath were removed,
followed by puncture site aftercare. The activated clotting
time was measured after the procedure to evaluate the
optimal time of arterial sheath removal and hemostasis.
The type of embolic protection device used depended
on the anatomical characteristics, plaque embolic poten-
tials, and localization and degree of the stenosis. The
most frequently used protection device was a FilterWire
(Boston Scientiﬁc, Natick, Mass) in 151 patients (47.3%),
followed by an Angiogard Rx (Cordis Corp, New Bruns-
wick, NJ) in 127 (39.8%), a Spider Fx (Covidien, Dublin,
Ireland) in 40 (12.5%), and an Emboshield (Abbot
Vascular, Temecula, Calif) in one (0.31%).
The most frequently used stent was a Carotid Wallstent
(Boston Scientiﬁc), in 158 patients (49.5%), followed by a
Protégé Rx (Covidien), in 76 (23.8%), and a Precise Rx
(Cordis Corp), in 49 (15.4%). The most rarely used stents
were the Crystallo Ideale (Medtronic, Minn), in 16 pa-
tients (5.01%), and the Xact (Abbot Vascular), in two pa-
tients (0.62%). The most frequently used balloons were
Cordis Aqua and Amia (Johnson & Johnson, New Bruns-
wick, NJ), followed by Ultrasoft and Gazelle (Boston
Scientiﬁc).
Follow-up protocol and primary and secondary end
points. Follow-up after the procedure was identical for all
patients: clinical control by the attending surgeon and co-
lor duplex ultrasound imaging at 1 month, 6 months,
1 year, and annually thereafter.
The end points for the current study encompassed
mayor adverse cardiovascular events, including myocardial
infarction (MI), stroke, and cardiovascular death (fatal MI,
Table I. Patients’ demographic and preoperative
characteristics
Variablesa Patients (N ¼ 319)
Gender
Male 191 (71)
Female 128 (29)
Age, years 64.99 6 7.87
Arterial hypertension 301 (94.4)
Hyperlipidemia 284 (89.02)
Smoking history 212 (66.5)
Diabetes mellitus 114 (35.7)
Heredity 162 (50.8)
Coronary artery disease 112 (35.1)
Previous MI 34 (10.6)
Previous CABG 27 (8.5)
Symptomatic patients 99 (31.03)
Asymptomatic patients 220 (68.96)
Contralateral ICA occlusion 19 (5.6)
Peripheral vascular disease 87 (27.3)
CABG, Coronary artery bypass grafting; ICA, internal carotid artery;
MI, myocardial infarction; TIA, transient ischemic attack.
aContinuous data are shown as mean 6 standard deviation and categoric
data as number (%).
Table II. Occurrence and characteristics of carotid
restenosis (CR) lesion
Variablesa Patients (N ¼ 319)
Average time of CR occurrence, years 4.07 6 3.96
Intimal hyperplasia 184 (57.7)
Novel atherosclerotic lesions 135 (42.3)
Plaque characteristic
Stable 291 (91.2)
Ulcerated with embolic potentialb 28 (8.8)
Calciﬁed 39 (12.2)
Proximal CCA lesion only 26 (8.2)
Bifurcation and ICA origin 247 (77.4)
Diffuse CCA and ICA origin 46 (14.4)
Short lesion (#15 mm) 238 (74.6)
Long lesion (>15 mm) 81 (25.4)
CCA, Common carotid artery; ICA, internal carotid artery.
aContinuous data are shown as mean 6 standard deviation and categoric
data as number (%).
bPlaque with ulcerated surface, echolucent.
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hematoma and recurrent restenosis.
The primary end points of the study were analyzed as
early results. Results >30 days after the procedure and
secondary end points were analyzed as long-term results.
Median follow-up was 49.8 6 22.8 months (range,
17-121 months). If signiﬁcant recurrent restenosis (>50%
symptomatic patients; >85% asymptomatic patients) was
registered, multidetector CT angiography was performed
for repeated angioplasty assessment.
All variables and risk factors that could predict the
outcome were analyzed as well: (1) demographics (age
and gender), (2) atherosclerosis risk factors (hypertension,
dyslipidemia, smoking, and family history), (3) diabetes mel-
litus, (4) coronary disease, (5) contralateral carotid occlu-
sion, (6) peripheral occlusive arterial disease, (7) time of
CR occurrence after eCEA, deﬁned as early (#2 years) or
late (>2 years); (8) previous TIA and stroke, (9) plaque
characteristics (degree of stenosis, quality, embolic potential,
calciﬁcations, length and localization), (10) predilatation,
and (11) type of stent and embolic protection devices used.
Statistical analysis. The normality of the data distri-
bution was tested using the Kolmogorov-Smirnov test.
Numeric variables were described using the arithmetic
mean and standard deviation. The c2 test or Fisher exact
test was used to test the signiﬁcance of differences in the
frequency distribution among the categories. To analyze
the current level of measurement of the variables, we
applied the Mann-Whitney test.
The Kaplan-Meier method was used for survival assess-
ment. Cox univariate and multivariate analyses were per-
formed to assess predictors of survival. Control covariates
(age, gender, type of stent and protection device, risk fac-
tors) were also analyzed using the multivariate Cox regres-
sion model. The Breslow (generalized Wilcoxon) method
was used for evaluation of the differences in the survival be-
tween the categories of patients. The minimum accepted
level of signiﬁcance of the ﬁrst order error was 0.05.
Data were statistically analyzed using SPSS 19.0 software
(SPSS/IBM Corp, Armonk, NY).
RESULTS
The overall patient demographic characteristics are re-
ported in Table I. Restenotic plaque characteristics are re-
ported in Table II. The average time of the occurrence of
restenosis was 4.07 6 3.96 years (range, 6 months-17
years). In 57.7% of patients, intimal hyperplasia was the
main reason for restenosis occurrence. Plaques consisting
of intimal hyperplasia occurred earlier after primary surgery
(3.54 6 3.46 years) than atherosclerotic lesions (4.78 6
4.26 years; P ¼ .048).
The femoral artery was the access site in 93.4% of the
patients, whereas the radial or brachial artery was used in
6.6% because of severe aortoiliac occlusive disease (4.7%),
previous aortic bifemoral bypass graft (1.2%), or abdominal
aortic aneurysm (0.6%).
Early results. All but one procedure ended with a
technical success (99.69%), which was deﬁned as thedeployment of the carotid stent or balloon angioplasty
alone. Six patients required multiple stents because of
complicated lesions. PTA was performed in 12 patients
without stent placement. Predilation was performed in 62
patients (19.4%), whereas postdilation was performed in
222 (69.6%).
In the early postoperative period, TIA occurred in 2.8%
of the patients and stroke in 1.6%, followed by one death of
a neurologic cause (0.3%; Table III). The most common
stent-related complication was arterial spasm (1.9%), which
resolved spontaneously in all cases.
In one patient (0.3%), stent thrombosis occurred
2 hours after the angioplasty. The patient presented with
contralateral weakness, and emergency CT angiography
revealed stent thrombosis. The patient underwent urgent
Table III. Early postprocedural results (#30 days)
Variable
Patients (N ¼ 319),
No. (%)
Residual stenosis (20%-30%) 7 (2.2)
Dissection of CCA 2 (0.6)
Spasm 6 (1.9)
Stent thrombosis 1 (0.3)
Conversion to open surgery 1 (0.3)
Hematoma/hemorrhage 7 (2.2)
TIA 9 (2.8)
Stroke 5 (1.6)
Mortality
Neurologic 1 (0.3)
Non-neurologic 0
CCA, Common carotid artery; TIA, transient ischemic attack.
Table IV. Long-term results after angioplasty and
carotid artery stenting (CAS) for carotid restenosis (CR)
after eversion carotid endarterectomy (eCEA)
Long-term results
Patients (N ¼ 319),
No. (%)
RR 14 (4.4)
Treatment for RR
Re-PTA 11 (3.4)
Redo surgery 3 (0.9)
Mortality
Neurologic 0
Non-neurologic 10 (3.13)
Coronary angioplasty 32 (10.0)
Fatal MI 2 (0.6)
Peripheral angioplastya 41 (12.9)
MI, Myocardial infarction; PTA, percutaneous transluminal angioplasty;
RR, recurrent restenosis.
aAortoiliac, femoropopliteal, distal crural.
Fig 1. Kaplan-Meier curve shows survival rate after stroke
following carotid angioplasty for recurrent stenosis. The standard
error of survival after stroke was 0.0031 at 1 month, 0.0062 at
30 months, and 0.0153 at 58 months.
Fig 2. Kaplan-Meier curve shows overall mortality after carotid
angioplasty for recurrent stenosis. The standard error of overall
survival rate was 0.0031 at 1 month, 0.0047 at 26 months, 0.0074
at 34 months, 0.0087 at 36 months, 0.0098 at 37 months, 0.0113
at 44 months, 0.0129 at 46 months, 0.0191 at 65 months, 0.0326
at 84 months, and 0.0609 after 98 months.
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interposition. Brain CT performed after the surgery
revealed ipsilateral acute ischemia; still, this patient
completely recovered due to emergency surgery and fast
revascularization.
Puncture site hematoma was veriﬁed in 2.2% of the
patients, and 1.3% of these were surgically treated. Three
patients (0.94%) were operated on for femoral access
hematoma, and one patient (0.31%) for hematoma after
brachial artery puncture. In two patients (0.6%), common
carotid artery dissection was noted and was resolved by
additional angioplasty and stenting.
Long-term results. No TIAs or strokes were veriﬁed
during the follow-up, and non-neurologic mortality was
3.13% (Table IV). Two patients died after fatal MIs (0.6%),
1 after cardiac surgery (0.3%), 1 (0.3%) after multi-organ
failure due to malignancy, and 7 lethal outcomes
occurred due to an unknown cause. Recurrent restenosis
occurred in 14 patients (4.4%). Repeated balloon angio-
plasty was performed in 12 patients, and graft interposition
was performed in two patients because of extensive and
calciﬁed lesions. All procedures were uneventful.The survival rate after stroke was 0.997 6 0.0031 after
1 year and 0.969 6 0.0153, both after 5 and 10 years
(Fig 1). Estimated mean was 116.939 6 1.376 months
(95% conﬁdence interval, 114.242-119.636 months).
Overall mortality was also assessed by Kaplan-Meier
method (Fig 2). The survival rate was 0.9976 0.0031 after
1 year, 0.949 6 0.0191 after 5 years, and 0.868 6 0.0609
after 10 years. Estimated mean survival time was
114.816 6 2.018 months (95% conﬁdence interval,
110.861-118.770 months).
Symptomatic vs asymptomatic CR. As reported in
Table I, 99 of 319 patients (31.03%) were symptomatic
and 220 (68.96%) were asymptomatic before CAS for
recurrent stenosis. Before carotid angioplasty and stenting,
Table V. Postprocedural results in symptomatic and
asymptomatic patients
Postprocedural
result
Asymptomatic
patients (n¼ 220),
Symptomatic
patients (n ¼ 99),
PNo. (%) No. (%)
Spasm 3 (1.3) 3 (3.03) NS
Stent thrombosis 1 (0.45) . NS
Hematoma/
hemorrhage
7 (3.18) . NS
TIA 4 (1.8) 5 (5.05) NS
Stroke 3 (1.3) 2 (2.02) NS
Early mortality
(<30 days)
Neurologic 1 (0.45) 0 NS
Non-neurologic 0 0 .
Late mortality 0 0 .
Neurologic . . .
Non-neurologic 10 (4.54) 0 .034
NS, Nonsigniﬁcant; TIA, transient ischemic attack.
Fig 3. Kaplan-Meier curve shows mortality in symptomatic (black
line) vs asymptomatic (blue line) patients after carotid angioplasty
for recurrent stenosis. The standard error of survival rate in
asymptomatic patients was 0.0045 at 1 month, 0.0046 at
26 months, 0.0112 at 34 months, 0.0133 at 36 months, 0.0153 at
37 months, 0.0177 at 44 months, 0.0205 at 46 months, 0.0316 at
65 months, 0.0696 at 84 months, and 0.1280 after 98 months
(>10%).
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and 2 had both TIA and stroke. Patients with nonhemi-
spheric symptoms (vertigo, dizziness, walking, and insta-
bility) were considered asymptomatic.
Preprocedural characteristics. Men comprised 69.7%
of the asymptomatic group vs 55.5% of the symptomatic
group, whereas women were 44.5% of the asymptomatic
group and 30.3% of the symptomatic group (P ¼ .016).
Patients with a smoking history were more common in
the symptomatic group than in the asymptomatic group
(76.8% vs 62.4%; P ¼ .012) group, as was contralateral in-
ternal carotid artery occlusion (10.1% vs 4.1%, P ¼ .036).
Signiﬁcant differences were observed when ischemic
symptoms were assessed by the degree of restenosis. As ex-
pected, ulcerated plaques were more likely to be symptom-
atic than plaques that occurred as a result of intimal
hyperplasia without ulcerations (P ¼ .005).
Postprocedural results. When symptomatic and
asymptomatic patients were compared by postprocedural
results, no signiﬁcant differences were found in any of the
evaluated outcomes except for non-neurologic mortality
(MI, cardiac morbidity, malignancy and sudden death of
unknown cause) during the follow-up period (4.54% in
asymptomatic group vs 0% in symptomatic group, P ¼
.034; Table V). A Kaplan-Meier curve describing the
mortality between the two groups is shown in Fig 3. All
lethal outcomes were noted in asymptomatic patients, with
a survival rate of 0.995 6 0.0045 after 1 year, 0.918 6
0.0316 after 5 years, and 0.730 6 0.128 after 10 years.
Variables inﬂuencing carotid angioplasty outcome.
The predictive value of different factors regarding outcome
after carotid angioplasty for restenosis is presented in
Table VI. Smoking history was highly predictive for post-
procedural TIA occurrence (all nine patients with TIA were
smokers), nonsmokers had a higher incidence for non-
neurologic mortality during the follow-up period (nine vs
two patients). Coronary artery disease was an important
predictor for non-neurologic mortality during the follow-
up period as well as for recurrent restenosis occurrence.
Female gender was associated with a higher incidence
of non-neurologic mortality during the follow-up period,
whereas plaque calciﬁcations were a signiﬁcant predictor
of recurrent restenosis occurrence. Carotid angioplasty
was performed at the bifurcation level in 10 of 14 patients
(71.4%) with recurrent restenosis.
The type of the stent and embolic protection device
used signiﬁcantly strongly predicted neurologic outcome
after the procedure. When the type of the stent was
analyzed, postprocedural TIA was most frequent in pa-
tients who received a Precise stent (six of 49 [12.2%]),
whereas the lowest incidence (0%) was noted in the 76 pa-
tients who received a Protégé stent. When we examined
embolic protection device inﬂuence on outcome, the high-
est statistical incidence of postprocedural TIA was noted in
patients in whom a Spider Fx device was used (ﬁve of 40
patients [12.5%]), whereas no postprocedural neurologic
ischemic events occurred in the 150 patients in the Filter-
Wire group.DISCUSSION
CR is one of the major complications that follow
carotid surgery.17,18 CR appears in two different forms:
early, caused by neointimal hyperplasia within the ﬁrst
24 months after CEA, and late (the result of new athero-
sclerotic lesions), which occurs >2 years after CEA.3,19
Two modalities are recommended for the treatment of
CR after CEA: CAS and redo surgery. Opponents of open
redo surgery for CR highlight the increased risk of cranial
nerve injury and postoperative morbidity due to recurrent
tissue trauma.20-23 Proponents of CAS report that CAS is
safe and reliable for CR treatment.11,24
Table VI. Distribution of evaluated variables and their predictive value
Evaluated variable Evaluated outcome Predictive value P
Smoking history Postprocedural TIA Signiﬁcant .032
Stent postdilatation Postprocedural stroke Signiﬁcant .031
Female gender Non-neurologic mortality during the follow-up Signiﬁcant .025
Smoking history Non-neurologic mortality during the follow-up High .012
Coronary artery disease Non-neurologic mortality during the follow-up High .015
Coronary artery disease Recurrent restenosis Extremely high .007
Site of restenotic plaque Recurrent restenosis Extremely high .009
Restenotic plaque calciﬁcation Recurrent restenosis Extremely high .003
Type of stent Postprocedural TIA Signiﬁcant .033
Type of cerebral protection device Postprocedural TIA High .001
TIA, Transient ischemic attack.
JOURNAL OF VASCULAR SURGERY
650 Radak et al September 2014Because of the controversy and conﬂicting opinions
concerning CR treatment, numerous studies have
compared CAS and redo surgical treatment.16,19,25 These
studies registered a similar outcome after CAS and redo
CEA, but CAS was still associated with a higher recurrent
restenosis rate during the follow-up, whereas redo surgery
had a higher incidence of cranial nerve injury.16,19,25
In the present study, the results of carotid angioplasty
were analyzed in patients with CR that occurred exclusively
after eCEA. No previously published studies have analyzed
only post-eCEA restenosis treated by PTA, with or without
stenting. The results of the present study revealed that CAS
is a safe and reliable procedure for CR treatment, with a low
rate of early and long-term post-procedural complications.
De Borst et al11 reported a 3.5% incidence of early TIA
and no strokes or deaths in patients with CAS for restenosis,
whereas signiﬁcant recurrent restenosis was veriﬁed in 19%
of their patients. Despite a longer follow-up, our study indi-
cated better long-term results with a lower incidence of
recurrent restenosis with a similar rate of early complications.
In our study, symptomatic patients were more likely to
be males and smokers in whom contralateral internal ca-
rotid artery occlusion was more commonly observed.
Despite the lower incidence of preprocedural ischemic
symptoms compared with symptomatic patients, asymp-
tomatic patients had higher mortality rate (4.54% vs 0%).
This could be because there were more asymptomatic pa-
tients (69% vs 31%) who were also signiﬁcantly older
(65.92 6 7.8 years vs 62.926 7.67 years; P ¼ .002). Simi-
larly as in the studies published so far,11,14,26 most of the
patients in our study were asymptomatic (69%); still, the
follow-up in the present study was signiﬁcantly longer
(range, 17-121 months). That no lethal outcomes were
veriﬁed in symptomatic patients might seem surprising;
however, the overall mortality rate was 3.13%, making
the results of the present study appropriate and authentic.
In addition to the early-term and long-term results, our
study highlights the importance of the procedural technical
details during the CAS that inﬂuence postprocedural
outcome. The highest rate of TIA was veriﬁed in patients
in whom a Precise stent (6 of 49 patients [12.2%]) and
in those in whom a Spider Fx cerebral protection device
(5 of 40 patients [12.5%]) was used.These facts are of great importance, especially when
taking into consideration that in a signiﬁcantly greater
number of patients, a Carotid Wallstent was used with a
lower rate of postprocedural ischemic events (3 of 158
[1.9%]). Similarly, a FilterWire cerebral protection device
was used in 150 patients, and no postprocedural complica-
tions were observed. As for other predictors, coronary ar-
tery disease and plaque calciﬁcations had a strong impact
on the recurrent restenosis rate, whereas female gender
and coronary artery disease inﬂuenced the higher incidence
of non-neurologic lethal outcome during the follow-up
period.
One important ﬁnding is that the present study con-
ﬁrms plaque calciﬁcation as a strong predictive factor for
recurrent restenosis occurrence. Smoking history was asso-
ciated with higher rate of postprocedural TIA but a lower
rate of non-neurologic mortality during the follow-up
period as well.
Thus, far no study has published similar results on the
effect of stent and cerebral protection device selection on
neurologic outcome after CAS in patients with CR. The re-
sults of the present study might provide important direc-
tions in future interventions to reduce the incidence of
postprocedural neurologic complications.
When the present results were compared with our pre-
viously reported results for surgical treatment of CR,10 a
higher incidence of early postprocedural complications
was noted after surgical treatment than after CAS (TIA:
7.6% vs 2.8%; stroke: 3.8% vs 1.6%; cranial nerve injury:
7.6% vs 0%).
According to our experience, we recommend carotid
angioplasty and stenting as the ﬁrst treatment modality in
patients with signiﬁcant carotid artery restenosis after
eCEA. However, if carotid angioplasty is not possible,
redo surgery is the preferable treatment option. This is
our algorithm for the treatment of patients with CR after
eCEA.
Limitations. This report compared many different
materials used for PTA and CAS. Although the study was
retrospective with prospectively collected data and involved
small numbers of complications and materials, the variation
between the variables, when signiﬁcant, might be of clinical
relevance. Furthermore, open repair was the preferable
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Volume 60, Number 3 Radak et al 651treatment option in the ﬁrst years of the study, and has
currently has almost been completely replaced by CAS.
We included patients treated only with balloon angio-
plasty without stenting as well those treated with CAS.
The reason for that choice was to present “real-world”
treatment for restenosis after eCEA.
Keeping in mind that there is no common agreed upon
protocol to assess the restenotic carotid plaque after CEA,
we used standard ultrasound characteristics for primary
atherosclerotic lesions, especially in the patients treated
by CEA in the beginning of last decade of the last century.
Our ultrasound criteria for restenosis diagnosis proved to
be reliable, as we demonstrated that ultrasound imaging
had a speciﬁcity of 97.7%, sensitivity of 100%, a positive-
predictive value of 98.4% and a negative-predictive value
of 100% compared with CT angiography.27
CONCLUSIONS
CAS is a safe and reliable procedure for CR treatment
after eCEA, with a low rate of postprocedural complica-
tions. Female gender, coronary artery disease, plaque calci-
ﬁcations, and smoking history are associated with adverse
outcome after CAS. The type of stent and cerebral embolic
protection device and their selection during the stenting
may inﬂuence the rate of postprocedural neurologic
ischemic events.
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